Clinical Trial Update: Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial of bortezomib combined with vorinostat in high-risk myelodysplastic syndrome or acute myeloid leukemia has been terminated; results posted in 2013…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Bortezomib (bortezomib)
• Vorinostat (vorinostat)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2013-02-25